Clinical Trials in Habikino, Japan
2 recruiting
Showing 1–10 of 10 trials
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
Dermatitis Atopic
Sanofi636 enrolled147 locationsNCT06241118
Recruiting
Phase 2
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
Atopic Dermatitis
UCB Biopharma SRL160 enrolled57 locationsNCT07277660
Recruiting
Phase 3
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
Healthy
Pfizer6,000 enrolled165 locationsNCT07160244
Recruiting
Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled779 locationsNCT03486873
Recruiting
Phase 2
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
Asthma
Eli Lilly and Company531 enrolled121 locationsNCT07219173
Recruiting
Phase 3
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
Pruritus
Sanofi284 enrolled91 locationsNCT05263206
Recruiting
Specified Drug-use Surveillance of Fabhalta Capsules
Paroxysmal nocturnal hemoglobinuria
Novartis Pharmaceuticals100 enrolled92 locationsNCT06606314
Recruiting
Phase 2
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
Eosinophilic Granulomatosis With PolyangiitisChurg-Strauss Syndrome
NS Pharma, Inc.45 enrolled34 locationsNCT06046222
Recruiting
Special Drug Use-results Surveillance of Tafinlar/Mekinist
BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
Novartis Pharmaceuticals110 enrolled68 locationsNCT06262919
Recruiting
Phase 2
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Novartis Pharmaceuticals224 enrolled99 locationsNCT06947993